prostate cancer

Showing 15 posts of 84 posts found.

Lynparza granted approval to treat prostate cancer in Japan

August 25, 2023
Research and Development Merck, Oncology, astra zeneca, prostate cancer

AstraZeneca and Merck (known as MSD outside the US and Canada) have received approval from the Japanese Ministry of Health, …

FDA approved Janssen’s Akeega for prostate cancer treatment

August 14, 2023
Research and Development Akeega, FDA, J&J, Janssen, Oncology, prostate cancer

The Janssen Pharmaceutical companies of Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved …


FDA approves Pfizer’s HRR mCRPC drug

June 21, 2023
Medical Communications FDA, Oncology, Pfizer, breast cancer, oncology, prostate cancer

US-based pharmaceutical and biotechnology company Pfizer has announced that the US Food and Drug Administration (FDA) has approved its homologous …

Medical cannabis formulation kills prostate cancer in laboratory tests

July 19, 2021
Sales and Marketing medical cannabis, prostate cancer

Apollon Formularies have announced its medical cannabis formulations were shown to be effective in killing both hormone-resistant and hormone-sensitive prostate …

New NICE recommendation for Astellas prostate cancer drug

June 8, 2021
Manufacturing and Production Astellas, NICE, prostate cancer

A newly published Final Appraisal Determination by NICE has recommended Astellas’ Xtandi (enzalutamide) plus androgen deprivation therapy (ADT), as an …


Lucida Medical gains CE marking for AI prostate cancer tech

June 1, 2021
Manufacturing and Production AI, MRI, NHS, prostate cancer

Cambridge-based AI company, Lucida Medical, has received CE marking for its new machine learning-based prostate cancer detection software, Prostate Intelligence …


Janssen sees promising PRO data for prostate cancer therapy

May 27, 2021
Janssen, prostate cancer

Janssen has announced patient-reported outcomes (PRO) data from the pre-specified final analysis of their Phase III TITAN study in patients …

MHRA sign

Astellas prostate cancer drug gets third approval from MHRA

May 12, 2021
Research and Development Astellas, MHRA, cancer research, cancer treatment, pharma, pharma news, prostate cancer

The MHRA has approved Astellas Pharma’s XTANDI (enzalutamide) drug for the treatment of a third form of prostate cancer, making …


AstraZeneca to collaborate with Alchemab on prostate cancer research

May 6, 2021
AstraZeneca, prostate cancer

AstraZeneca have announced a new collaboration with Cambridge-based biotech company Alchemab, with the aim of accelerating prostate cancer research. Alchemab …

Bayer’s Nubeqa combo approved in Europe for non-metastatic castration-resistant prostate cancer

March 31, 2020
Manufacturing and Production, Research and Development Bayer, Cancer, Europe, Nubeqa, prostate cancer

The European Commission has given the green light to Bayer’s non-steroidal androgen receptor inhibitor Nubeqa (darolutamide), jointly developed with Orion, …

Prostate Cancer becomes most commonly diagnosed cancer in England

January 28, 2020
Manufacturing and Production Cancer, Cancer diagnoses, NHS England, breast cancer, prostate cancer

Prostate cancer has overtaken breast cancer to be the most commonly diagnosed cancer for the first time in England, latest …


NHS Scotland recommends Janssen’s Zytiga combo for newly diagnosed prostate cancer

January 13, 2020
Sales and Marketing Cancer, NHS, Scotland, nhs scotland, prostate cancer

Janssen’s Zytiga (abiraterone acetate) has just been approved by the Scottish Medicines Consortium (SMC), meaning that male patients on the …


Largest drop ever in US cancer mortality rates, new study shows

January 9, 2020
Business Services Cancer, brain cancer, lung cancer, prostate cancer

The overall cancer mortality rate in the US fell by 2.2% from 2016 to 2017, the largest ever annual decline …


AstraZeneca sells Amrimidx and Casodex European rights to Juvisé Pharmaceuticals

December 20, 2019
Medical Communications AstraZeneca, Cancer, Juvise, breast cancer, prostate cancer

AstraZeneca has announced that it has agreed to sell the rights to Arimidex (anastrozole) and Casodex (bicalutamide) in Europe, as …

FDA approves Pfizer and Astellas Pharma’s prostate cancer drug

December 17, 2019
Manufacturing and Production Astellas Pharma, Cancer, FDA, Pfizer, Xtandi, prostate cancer

The FDA has approved Pfizer and Astellas Pharma’s Xtandi (enzalutamide) to treat patients with a type of prostate cancer. The …

Latest content